# Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

Study · id `cardio:ct-nct01425359` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01425359](<https://clinicaltrials.gov/study/NCT01425359>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01425359

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 949 participants.

## Technical summary

Registry record NCT01425359. Randomized; quadruple masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2012-10 (actual). Results posted on 2014-11-04.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 949 participants (enrolled count; ClinicalTrials.gov record NCT01425359, source copy `cardio:ctgov-nct01425359-2014-11-04`, retrieved 2026-10-26)
- Start date: 2011-09 (registry gives no type) (ClinicalTrials.gov record NCT01425359, source copy `cardio:ctgov-nct01425359-2014-11-04`, retrieved 2026-10-26)
- Primary completion: 2012-10 (actual) (ClinicalTrials.gov record NCT01425359, source copy `cardio:ctgov-nct01425359-2014-11-04`, retrieved 2026-10-26)
- Completion: 2012-10 (actual) (ClinicalTrials.gov record NCT01425359, source copy `cardio:ctgov-nct01425359-2014-11-04`, retrieved 2026-10-26)
- Results first posted: 2014-11-04 (ClinicalTrials.gov record NCT01425359, source copy `cardio:ctgov-nct01425359-2014-11-04`, retrieved 2026-10-26)
- Countries: United States; Belarus; Bulgaria; Canada; Czechia; Georgia; Germany; Israel; Poland; Russia; Serbia; Slovakia; Slovenia; Ukraine (ClinicalTrials.gov record NCT01425359, source copy `cardio:ctgov-nct01425359-2014-11-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01425359-2014-11-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
- Acronym: TERISA
- Condition: Angina Pectoris
- Condition: Coronary Artery Disease
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Ranolazine
- Intervention (Drug): Ranolazine placebo
- Lead sponsor: Gilead Sciences
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Angina pectoris (`cardio:angina-pectoris`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Gilead Sciences (`cardio:org-gilead-sciences`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina) (`cardio:pubmed-23500237`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Comparison of the Seattle Angina Questionnaire With Daily Angina Diary in the TERISA Clinical Trial (`cardio:pubmed-25249560`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: cc9d2c90420a15ea2439a81f64f0ca5d2d3a69af459d4ab1827c0e6580b5a971
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
